Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Chemotherapies and future directions in metastatic colorectal cancer

Chemotherapies and future directions in metastatic colorectal cancer Summary Substantial progress has been achieved in the management of metastatic colorectal cancer (mCRC) over the last two decades. The overall survival has increased from 10 months to more than 30 months. These improvements are due to the integration of multiple cytotoxic agents and targeted therapies, as well as individualized treatment strategies using molecular and clinical factors. More specific, molecular characteristics such as RAS mutation status and clinical factors such as performance status, tumor burden, tumor-related symptoms and comorbidities are crucial in selecting treatment strategies. Here I review the landscape of cytotoxic chemotherapy for mCRC, regional chemotherapy strategies to accumulate cytotoxics within the tumor and reflect on future directions for treatment of mCRC. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Chemotherapies and future directions in metastatic colorectal cancer

Loading next page...
 
/lp/springer-journals/chemotherapies-and-future-directions-in-metastatic-colorectal-cancer-9yAfwHPhus
Publisher
Springer Journals
Copyright
2017 Springer-Verlag GmbH Austria
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0351-3
Publisher site
See Article on Publisher Site

Abstract

Summary Substantial progress has been achieved in the management of metastatic colorectal cancer (mCRC) over the last two decades. The overall survival has increased from 10 months to more than 30 months. These improvements are due to the integration of multiple cytotoxic agents and targeted therapies, as well as individualized treatment strategies using molecular and clinical factors. More specific, molecular characteristics such as RAS mutation status and clinical factors such as performance status, tumor burden, tumor-related symptoms and comorbidities are crucial in selecting treatment strategies. Here I review the landscape of cytotoxic chemotherapy for mCRC, regional chemotherapy strategies to accumulate cytotoxics within the tumor and reflect on future directions for treatment of mCRC.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Sep 1, 2017

References